Last update 21 Dec 2024

Anti-CD19 CAR-T cell therapy(The First Affiliated Hospital of Nanchang University)

Overview

Basic Info

Drug Type
CAR-T
Synonyms-
Target
CD19
Mechanism
CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), Gene transference
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [2]
Active Indication-
Inactive Indication
LymphomaRefractory B Acute Lymphoblastic LeukemiaRefractory Multiple Myeloma+ [1]
Originator Organization
The First Affiliated Hospital of Nanchang University
Active Organization-
Inactive Organization
The First Affiliated Hospital of Nanchang University
Drug Highest PhasePendingPhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with Anti-CD19 CAR-T cell therapy(The First Affiliated Hospital of Nanchang University)
NCT04194931 / Unknown statusPhase 1IIT
Study Evaluating the Safety and Efficacy With Sequential Infusion of Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma
NCT04196205 / Unknown statusPhase 1/2IIT
Study Evaluating the Safety and Efficacy With Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas
100 Clinical Results associated with Anti-CD19 CAR-T cell therapy(The First Affiliated Hospital of Nanchang University)
Login to view more data
100 Translational Medicine associated with Anti-CD19 CAR-T cell therapy(The First Affiliated Hospital of Nanchang University)
Login to view more data
100 Patents (Medical) associated with Anti-CD19 CAR-T cell therapy(The First Affiliated Hospital of Nanchang University)
Login to view more data
100 Deals associated with Anti-CD19 CAR-T cell therapy(The First Affiliated Hospital of Nanchang University)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
LymphomaPhase 2
CN
The First Affiliated Hospital of Nanchang University
01 Dec 2019
Refractory B Acute Lymphoblastic LeukemiaPhase 2
CN
The First Affiliated Hospital of Nanchang University
01 Dec 2019
Refractory Multiple MyelomaPhase 1
CN
The First Affiliated Hospital of Nanchang University
01 Dec 2019
Relapse multiple myelomaPhase 1
CN
The First Affiliated Hospital of Nanchang University
01 Dec 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free